Camptothecin ADC Payload Structure for Stability and Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current camptothecin derivatives in antibody-drug conjugates (ADCs) lack optimal therapeutic efficacy and safety, necessitating the development of improved compounds with enhanced inhibitory activity against tumor cells, plasma stability, bystander effect, and in vivo targeting capabilities.
Innovation Solution
Development of compounds with specific structural features, including heterocyclyl and carbocyclyl rings substituted with various functional groups, linked by peptide residues and other moieties, to enhance targeting, inhibitory, and stability properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives are used in ADCs, then anti-tumor effect is achieved by inhibiting topoisomerase I, but therapeutic effect and safety are not optimal
Solution Approach 1:
The patent modifies the chemical structure of camptothecin derivatives by changing parameters such as substituting different groups at positions R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100 to optimize both therapeutic efficacy and safety profile. This structural parameter optimization allows the compound to maintain topoisomerase I inhibition while reducing off-target effects and improving pharmacokinetic properties.
Solution Approach 2:
The patent creates composite structures by combining camptothecin core with various substituents including heterocyclic groups, aromatic groups, and linker moieties. These composite molecular structures integrate multiple functional elements that work synergistically to enhance tumor targeting, improve plasma stability, and maintain cytotoxic activity against topoisomerase I while reducing systemic toxicity.
2Reliability
If camptothecin derivatives are developed for ADCs, then inhibitory activity against tumor cells is achieved, but plasma stability is insufficient
Solution Approach 1:
The patent introduces stable linker intermediaries between the camptothecin cytotoxic payload and the ADC structure. These intermediary linkers are designed to be resistant to premature cleavage in plasma while remaining cleavable under specific intracellular conditions. The linker structures include stable bonds that prevent hydrolysis and degradation in the plasma environment, thereby maintaining the integrity of the ADC complex during circulation.
Solution Approach 2:
The patent modifies chemical parameters of the camptothecin derivative structure, particularly at positions that are susceptible to plasma degradation. By changing substituent groups and their electronic properties, the patent enhances the kinetic stability of the molecule against plasma esterases and other degradative enzymes, while preserving the essential topoisomerase I inhibitory activity.
3Reliability
If camptothecin derivatives are used, then topoisomerase I inhibition is achieved, but bystander effect and in vivo targeting capability are limited
Solution Approach 1:
The patent segments the ADC into distinct functional modules: a targeting antibody, a stable linker, and the camptothecin cytotoxic payload. This segmentation allows the antibody to provide specific in vivo targeting to tumor cells expressing the relevant antigen, while the camptothecin component provides the cytotoxic effect. The modular design also enables the camptothecin to exert bystander effect by diffusing to adjacent tumor cells that may not express the target antigen, thereby expanding the therapeutic effect beyond directly targeted cells.
Data Source
Figure 1~2
Figure 3~4
Figure 5~7
AI summary
The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.